Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats (Rattus norvegicus)

Journal of the American Association for Laboratory Animal Science

Volumn 53, Issue 2, 2014, Pages 193-197

  Chum, Helen H ^a   Jampachairsri, Katechan ^b   McKeon, Gabriel P ^c   Yeomans, David C ^a   Pacharinsak, Cholawat ^a   Felt, Stephen A ^a  

^a STANFORD UNIVERSITY   (United States)

^b NARESUAN UNIVERSITY   (Thailand)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DRUG EFFECT; HYPERSENSITIVITY; INCISION; LATENT PERIOD; LETHARGY; MALE; MECHANICAL STIMULATION; NONHUMAN; POSTOPERATIVE PAIN; RAT; RATTUS NORVEGICUS; SEDATION; SLEEP; SUSTAINED DRUG RELEASE; THERMAL STIMULATION;

ANALGESICS, OPIOID; ANIMAL WELFARE; ANIMALS; BUPRENORPHINE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; MALE; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896762859     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brennan MP, Sinusas AJ, Horvath TL, Collins JG, Harding MJ. 2009. Correlation between body weight changes and postoperative pain in rats treated with meloxicam or buprenorphine. Lab Anim (NY) 38:87-93.
2. Brennan TJ, Vandermeulen EP, Gebhart GF. 1996. Characterization of a rat model of incisional pain. Pain 64:493-501. (Pubitemid 26180156)
3. Carbone ET, Lindstrom KE, Diep S, Carbone L. 2012. Duration of action of sustained-release buprenorphine in 2 strains of mice. J Am Assoc Lab Anim Sci 51:815-819.
4. Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E. 2005. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507:87-98. (Pubitemid 40126844)
5. Clark JA Jr, Myers PH, Goelz MF, Thigpen JE, Forsythe DB. 1997. Pica behavior associated with buprenorphine administration in the rat. Lab Anim Sci 47:300-303.
6. Cowan A. 1992. Buprenorphine and gastrointestinal transit in rats: effect of naloxone on the biphasic dose-response curve. Clin Exp Pharmacol Physiol 19:47-49.
7. Cowan A, Doxey JC, Harry EJ. 1977. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 60:547-554. (Pubitemid 8149540)
8. Cowan A, Lewis JW, Macfarlane IR. 1977. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545. (Pubitemid 8149539)
9. Curtin LI, Grakowsky JA, Suarez M, Thompson AC, DiPirro JM, Martin LB, Kristal MB. 2009. Evaluation of buprenorphine in a postoperative pain model in rats. Comp Med 59:60-71.
10. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. 2005. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94:825-834. (Pubitemid 40754001)
11. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. 2006. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96:627-632.
12. Evans HC, Easthope SE. 2003. Transdermal buprenorphine. Drugs 63:1999-2010. (Pubitemid 37222571)
13. Foley PL, Liang H, Crichlow AR. 2011. Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats. J Am Assoc Lab Anim Sci 50:198-204.
14. Forbes N, Brayton C, Grindle S, Shepherd S, Tyler B, Guarnieri M. 2010. Morbidity and mortality rates associated with serial bleeding from the superficial temporal vein in mice. Lab Anim (NY) 39:236-240.
15. Gomez-Flores R, Weber RJ. 2000. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 48:145-156. (Pubitemid 30608671)
16. Hutchings DE, Zmitrovich AC, Hamowy AS, Liu PY. 1995. Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat. Neurotoxicol Teratol 17:419-423.
17. Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
18. Jessen L, Christensen S, Bjerrum OJ. 2007. The antinociceptive efficacy of buprenorphine administered through the drinking water of rats. Lab Anim 41:185-196. (Pubitemid 46733406)
19. Kalliokoski O, Jacobsen KR, Hau J, Abelson KS. 2011. Serum concentrations of buprenorphine after oral and parenteral administration in male mice. Vet J 187:251-254.
20. Karas AZ. 2002. Postoperative analgesia in the laboratory mouse, Mus musculus. Lab Anim (NY) 31:49-52. (Pubitemid 36707305)
21. Leach MC, Forrester AR, Flecknell PA. 2010. Influence of preferred foodstuffs on the antinociceptive effects of orally administered buprenorphine in laboratory rats. Lab Anim 44:54-58.
22. Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. 1994. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 51:1539-1554. (Pubitemid 24186161)
23. Lutfy K, Cowan A. 2004. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402. (Pubitemid 39276631)
24. Martinez EA, Hartsfield SM, Melendez LD, Matthews NS, Slater MR. 1997. Cardiovascular effects of buprenorphine in anesthetized dogs. Am J Vet Res 58:1280-1284. (Pubitemid 27479321)
25. Matsumiya LC, Sorge RE, Sotocinal SG, Tabaka JM, Wieskopf JS, Zaloum A, King OD, Mogil JS. 2012. Using the mouse grimace scale to reevaluate the efficacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim Sci 51:42-49.
26. McKeon GP, Pacharinsak C, Long CT, Howard AM, Jampachaisri K, Yeomans DC, Felt SA. 2011. Analgesic effects of tramadol, tramadol-gabapentin, and buprenorphine in an incisional model of pain in rats (Rattus norvegicus). J Am Assoc Lab Anim Sci 50:192-197.
27. Mohawk JA, Lee TM. 2005. Restraint stress delays reentrainment in male and female diurnal and nocturnal rodents. J Biol Rhythms 20:245-256. (Pubitemid 40646945)
28. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA. 2010. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10:428-450.
29. Swindle MM, Volger GA, Fulton LK, Marini RP, Popilskis S. 2002. Preanesthesia, anesthesia, analgesia, and euthanasia, p 955-1003. In: Fox FG, Anderson LC, Loew FM, Quimby FW, editors. Laboratory animal medicine. New York (NY): Academic Press.
30. Virk MS, Arttamangkul S, Birdsong WT, Williams JT. 2009. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci 29:7341-7348.
31. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. 1994. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580. (Pubitemid 24192243)
32. Wheeler-Aceto H, Cowan A. 1991. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 195:411-413.
33. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. 2008. Pharmacokinetic- pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 25:183-193.
34. Yun M, Jeong S, Pai C, Kim S. 2010. Pharmacokinetic-pharmacodynamic modeling of the analgesic effect of bupredermTM, in mice. Health 2:824-831.